Abstract:Inflammation is associated with a variety of diseases. The hallmark of inflammation is leukocyte infiltration at disease sites in response to pathogen- or damage-associated chemotactic molecular patterns (PAMPs and MAMPs), which are recognized by a superfamily of seven transmembrane, Gi-protein-coupled receptors (GPCRs) on cell surface. Chemotactic GPCRs are composed of two major subfamilies: the classical GPCRs and chemokine GPCRs. Formyl-peptide receptors (FPRs) belong to the classical chemotactic GPCR subfamily with unique properties that are increasingly appreciated for their expression on diverse host cell types and the capacity to interact with a plethora of chemotactic PAMPs and MAMPs. Three FPRs have been identified in human: FPR1-FPR3, with putative corresponding mouse counterparts. FPR expression was initially described in myeloid cells but subsequently in many non-hematopoietic cells including cancer cells. Accumulating evidence demonstrates that FPRs possess multiple functions in addition to controlling inflammation, and participate in the processes of many pathophysiologic conditions. They are not only critical mediators of myeloid cell trafficking, but are also implicated in tissue repair, angiogenesis and protection against inflammation-associated tumorigenesis. A series recent discoveries have greatly expanded the scope of FPRs in host defense which uncovered the essential participation of FPRs in step-wise trafficking of myeloid cells including neutrophils and dendritic cells (DCs) in host responses to bacterial infection, tissue injury and wound healing. Also of great interest is the FPRs are exploited by malignant cancer cells for their growth, invasion and metastasis. In this article, we review the current understanding of FPRs concerning their expression in a vast array of cell types, their involvement in guiding leukocyte trafficking in pathophysiological conditions, and their capacity to promote the differentiation of immune cells, their participation in tumor-associated inflammation and cancer progression. The close association of FPRs with human diseases and cancer indicates their potential as targets for the development of therapeutics.

Identification of FAM 3 D as a novel endogenous chemotaxis agonist for the FPRs ( formyl peptide receptors )

Identification of Fam3d As A New Endogenous Chemotaxis Agonist for the Formyl Peptide Receptors

Identification of neutrophil granule protein cathepsin G as a novel chemotactic agonist for the G protein-coupled formyl peptide receptor

Receptors for chemotactic formyl peptides as pharmacological targets

FAM19A4 is a Novel Cytokine Ligand of Formyl Peptide Receptor 1 (FPR1) and is Able to Promote the Migration and Phagocytosis of Macrophages.

Molecular recognition of formylpeptides and diverse agonists by the formylpeptide receptors FPR1 and FPR2

International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family

Formyl peptide receptors: a promiscuous subfamily of G protein-coupled receptors controlling immune responses

The Contribution of Chemoattractant GPCRs, Formylpeptide Receptors, to Inflammation and Cancer

Interplay between signaling via the formyl peptide receptor (FPR) and chemokine receptor 3 (CCR3) in human eosinophils

Novel Small‐molecule Agonists of Human Formyl Peptide Receptors and Pharmacophore Models of their Recognition

Regulation of inflammation by members of the formyl-peptide receptor family

Identification and functional characterization of allosteric agonists for the G protein-coupled receptor FFA2

The main functions and structural modifications of tripeptide N-formyl-methionyl-leucyl-phenylalanine (fMLP) as a chemotactic factor

Structural basis for recognition of N-formyl peptides as pathogen-associated molecular patterns

Strategies for positioning fluorescent probes and crosslinkers on formyl peptide ligands

The ligand binding site of the formyl peptide receptor maps in the transmembrane region

FAM3D regulation of head and neck squamous cell carcinoma behaviour through the EMT pathway

Functional activation of the formyl peptide receptor by a new endogenous ligand in human lung A549 cells

Structural and functional characterization of the endogenous agonist for orphan receptor GPR3

Pan-cancer analysis and experimental validation of FPR3 as a prognostic and immune infiltration-related biomarker for glioma